Trials / Completed
CompletedNCT00531557
Double Protease Inhibitor to Darunavir Switch Study
Phase IV Cohort Study Assessing Feasibility of Substituting Double Ritonavir-boosted Protease Inhibitors With Ritonavir-boosted Darunavir in HIV-infected Individuals With Viral Suppression on Highly Active Antiretroviral Therapy.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- St Stephens Aids Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to study the effects of switching from an antiretroviral combination that includes two ritonavir boosted protease inhibitors to replacement of these two protease inhibitors with a new protease inhibitor called Darunavir (also boosted with ritonavir). The study will investigate the effect of the switch on viral load (the levels of the HIV virus in the blood), on immunological parameters (CD4 count) and on other safety parameters and also on quality of life. In a subgroup of patients the impact of the switch on the body's response to the hormone insulin will also be measured (Euglycaemic clamp sub group)
Detailed description
HIV-RNA and CD4+ cell count to monitor virological and immunological response on switching to DRV/r. Routine safety bloods to include haematology and biochemistry (including U\&E, fasted glucose and insulin, liver function test, fasting cholesterol and triglycerides and serum lactate measurements). Quality of life EuroQOL questionnaires at baseline, and throughout the study to evaluate quality of life in the continued treatment/ treatment switch arms. A sub group of 10 patients will undergo two euglycaemic clamp procedures in order to determine the extent of glucose disposal. The first clamp will be performed prior to the switching from a double boosted PI therapy to DRV/r and the second one following administration of DRV/r for 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darunavir ritonavir |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2007-09-19
- Last updated
- 2010-08-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00531557. Inclusion in this directory is not an endorsement.